By S. Kan. Muhlenberg College. 2018.
With the exception of 1 trial that enrolled adults with severe depression and suicidality (mean MADRS of 35 discount 400 mg viagra plus with mastercard. History of inadequate response 430-435 buy 400 mg viagra plus amex, 437-442, 444-446 A total of 17 trials enrolled adults who had previously had an inadequate response to 1 or more antidepressant medication. These trials varied in the number, type, and length of historical failed antidepressant medications that were required for enrollment. Most commonly, trials required potential enrollees to have had an inadequate response to at least 1 antidepressant of any type, as given at adequate doses, for more than 6 weeks. The shortest 438 duration requirement was 4 weeks for a single prior trial of antidepressant medication. Only 1 444 trial required a history of response failure to antidepressants of 2 different classes. In the majority of trials, before being randomized to an atypical antipsychotic, all participants were required to complete a phase of open-label treatment with an antidepressant in order to prospectively verify inadequate response. The exceptions to this were in trials of 430, 431 438, 442 extended-release quetiapine and risperidone, in which enrollment was based only or at least partly on patient report of historical courses of inadequate response. Atypical antipsychotic drugs Page 103 of 230 Final Report Update 3 Drug Effectiveness Review Project As illustrated by the following descriptions, the prospective antidepressant treatment failure phases differed in the specific types of antidepressant medications used, the length of treatment, and the criteria used to define nonresponse. In trials of aripiprazole, inadequate response was established based on a HAM-D-17 reduction of less than 50% after 8 weeks of treatment with either escitalopram 10 or 20 mg, fluoxetine 20 or 40 mg, paroxetine controlled release 37. In trials of olanzapine, various methods were used to confirm treatment resistance. The earliest trial of olanzapine required a HAM-D-21 score of above 20 444 points following a 6-week trial of fluoxetine 20 to 60 mg. The next 2 trials of olanzapine required less than 30% improvement in MADRS total score following 7 weeks of treatment with 445 434 either nortriptyline 104. The most recent trials of olanzapine required either less than 25% decrease in HAM-D-17 score, a HAM-D-17 score of 18 or above, or a 15% or less decrease in HAM-D-17 between week 7 and 446 8 after 8 weeks of fluoxetine 47. In trials of risperidone, suboptimal response was established based on a Clinical Global Impression-Severity of Illness (CGI-S) 438 score of 4 or greater after 4 weeks on any antidepressant or a MADRS score of 15 or above 437 after 5 weeks on any antidepressant. Regimen and dosage The majority of trials (N=19) evaluated the strategy of augmenting standard antidepressant 432, 433, 439 434, 444-446 medications with atypical antipsychotics, including aripiprazole, olanzapine, 430, 431 436, 440, 447 437, 438, 441, extended-release quetiapine, immediate-release quetiapine, risperidone, 442 435 and ziprasidone. Mean dosages of atypical antipsychotics ranged from 10. In shorter-term trials, aripiprazole, extended-release quetiapine, immediate-release quetiapine, and risperidone were added to a variety of antidepressants, whereas olanzapine, and ziprasidone were each only studied in combination with a single antidepressant. Olanzapine was only studied in combination with fluoxetine and compared with fluoxetine, olanzapine, nortriptyline, and venlafaxine monotherapies. Ziprasidone was only studied in combination with sertraline and compared with sertraline monotherapy. Therefore, the evidence for olanzapine and ziprasidone applies to more limited situations than the evidence for aripiprazole, extended- release quetiapine, immediate-release quetiapine, and risperidone. Likewise, in the longer-term trial of risperidone augmentation, it was only studied in combination with citalopram and, thus, 441 has limited applicability. Placebo-controlled trials of atypical antipsychotic monotherapy were only found for 452 448-451, 453, 454 immediate-release quetiapine and extended-release quetiapine. Additionally, all patients in the trial of immediate-release quetiapine were undergoing 452 weekly sessions of cognitive behavioral therapy. In 2 shorter-term trials of extended-release 454 453, 454 quetiapine, participants were randomized to fixed dosages of 50 mg, 150 mg, or 300 453, 454 mg. In the remaining shorter-term trials, including the trials in adults with a mean age of 451 71. After 2 weeks, participants with an inadequate response were titrated to 300 mg. Similarly, in a longer-term trial, monotherapy with extended-release Atypical antipsychotic drugs Page 104 of 230 Final Report Update 3 Drug Effectiveness Review Project 450 quetiapine was initiated at 50 mg and titrated to 150 mg after 3 to 4 days. Dosages were then adjusted to 50 mg, 150 mg, or 300 mg based on clinical judgment. Effectiveness Relapse prevention Monotherapy Extended-release quetiapine is distinguished as the only atypical antipsychotic to have any long- term evidence of efficacy as monotherapy maintenance treatment from a controlled trial (52 450 weeks).
Given the demonstrable to a reversal of ﬁbrosis in MF viagra plus 400 mg with amex. The pathogenetic mechanisms activity of thalidomide analogs in improving anemia in MF proven 400mg viagra plus, there underlying the development of ﬁbrosis in MF are poorly are combination trials under way of ImiDs with other agents, understood. Although MF has been established to be a clonal including JAK inhibitors, in an effort to optimize the clinical disorder of pluripotent stem cell origin, the ﬁbroblasts have been activity of this class of drugs in MF (Table 2). The BM ﬁndings in MF include increases in the numbers of stromal cells and in levels of extracellular matrix IFN proteins, angiogenesis, and osteosclerosis. Multiple mechanisms have been proposed for IFN- activity in myeloid neoplasia, including effects on immunomodulatory cells Monoclonal antibodies such as T cells and NK cells, induction of proapototic genes, A current pathogenetic hypothesis with regard to the genesis of suppression of proliferation of hematopoietic progenitor cells, and 38 ﬁbrosis in MF is that clonal megakaryocytes secrete ﬁbrogenic and inhibition of angiogenesis. IFN- at conventional doses in estab- 46,47 angiogenic cytokines including TGF and MMP-9. A common lished MF is associated with signiﬁcant myelosuppression and theme emerging from several murine models of MF is that there nonhematologic toxicities such as fatigue that have limited its use in is a signiﬁcant association between increased numbers of mega- MF. With the availability of more tolerable pegylated preparations karyocytes and the development of an extracellular matrix and the demonstration that pegylated IFN can induce molecular typical of MF, and these ﬁndings lend credence to the hypothesis responses in polycythemia vera, there has been a recent interest in that megakaryocytes play a central role in ﬁbrogenesis. Novel agents targeting pathways downstream of the JAK/STAT signaling pathway in MF. Activated JAK2 signals through and activates downstream signaling intermediates such as STAT5, RAS/MAPK, and PI3K/AKT/mTOR pathways, leading to effects on proliferation and survival of MPN cells. JAK proteins can be down-modulated by the use of HSP90 inhibitors or HDAC inhibitors, which lead to targeting of both wild-type and mutant proteins for degradation by the proteosomal system. PI3K/AKT inhibitors, mTOR inhibitors, MEK inhibitors, and STAT inhibitors can inhibit the respective signaling intermediates downstream of JAK/STAT pathway. DNMT inhibitors can potentially reverse epigenetic silencing of various genes including the SOCS genes, which are negative regulators of the JAK/STAT signaling pathway. There several signaling intermediates downstream of the JAK/ The trial was terminated early due to drug supply issues after STAT signaling pathway (Figure 3) that constitute rational therapeu- enrollment of just 3 patients. The PI3K/AKT/mammalian target of rapamycin TGF in MF is supported by a recent study identifying abnormal (mTOR) pathway has been shown to be dysregulated in MPNs and genetic signatures in TGF 1 signaling in the spleen and BM AKT activation has been found to be critical for JAK2V617F- from the GATA-1low mouse, a murine model of MF. AKT and mTOR inhibitors have of TGF 1 signaling in this mouse model normalized this been associated with growth inhibition of primary MPN cells and aberrant gene expression signature, restored hematopoiesis and cell lines in vitro. These ﬁndings have led to the clinical investiga- megakaryocyte development, and reduced ﬁbrosis, neovascular- tion of mTOR inhibitors in MF. A minority of patients (15%- monoclonal antibody against lysyl oxidase (LOX)-like protein 2. LOX is a copper-dependent enzyme that initiates the covalent Although known targets of mTOR such as phosphor-p70S6K were cross-linking of collagen or elastin and was shown to be abundant in identiﬁed as potential biomarkers of response to the agent, there was the GATA-1low mouse, which is characterized by signiﬁcant MF and no signiﬁcant effect on MF-related biomarkers such as JAK2V617F high levels of low-ploidy megakaryocytes. Inhibition of LOX allelic burden, circulating CD34 cells, or cytokine levels. The drug enzymatic activity led to a signiﬁcant improvement of the ﬁbrotic was well tolerated, with grade 1-2 stomatitis being the most phenotype, leading to the speculation that LOX is a potential common toxicity. Combinations of JAK inhibitors and PI3K Aurora kinase inhibitors inhibitors may also be reasonable (Table 2) based on emerging Another potential target of the megakaryocyte-ﬁbrosis axis are preclinical evidence that suggests synergy. In acute megakaryocytic leukemia, a disease with a dismal prognosis characterized by expansion of immature mega- karyocytes and profound BM ﬁbrosis, aurora kinase A was identi- How I treat MF in the JAK kinase inhibitor era ﬁed as a mediator of polyploidization of malignant megakaryocytes. Given the variability in outcome associated with MF, a comprehen- Aurora kinase A inhibition in acute megakaryocytic leukemia led to sive assessment including risk stratiﬁcation according to contempo- apoptosis of malignant megakaryocytes and induced polyploidiza- rary prognostic scoring models such as the Dynamic International tion and expression of mature megakaryocyte markers. I use a watch and wait led to the speculation that aurora kinase A could be a valid approach in asymptomatic lower (low- and intermediate-1) risk therapeutic target in MF, and there are ongoing preclinical studies to patients, whereas those with higher (intermediate-2 and high-) risk validate these assertions. Given the emerging data for Hematology 2013 549 Figure 4. The DIPSS can be used for risk stratiﬁcation at any time point during the course of MF. Prognostic variables are each assigned a score of 1 point, except for anemia, which is assigned a score of 2 points.
Methods and results for 2 pairs of protocols (TRX101998 and TRX101999; TRX103632 and TRX103635) are fully published in 2 116 cheap 400mg viagra plus mastercard, 117 journal articles generic viagra plus 400mg line, respectively. Methods and results for protocols TRX106571 and TRX106573 had not yet been published at the time of this report, but were accessed from the summary reports available on the manufacturer’s clinical trial registry website (http://www. Protocols TRX101998 and TRX101999 used parallel designs and were rated good quality. Protocols TRX106571 and TRX106573 used crossover designs to specifically evaluate efficacy and harms in adults with a history of poor response or intolerance to previous triptan treatment. Protocols TRX106571 and TRX106573 were rated fair-quality mainly because the summary report only provided combined results for both crossover periods, which did not appear to be assessed or adjusted for potential order effects. Protocols TRX103632 117 and TRX103635 used 4-period crossover designs to evaluate consistency across 3 attacks. Patients were randomized to 1 of 5 treatment sequences, 4 of which contained 1 interspersed placebo treatment period. One sequence that contained 4 consecutive treatment periods of ® Treximet was included for comparison in order to assess period effects and within-subject consistency. Results for protocols TRX103632 and TRX103635 were reported separately for the first period only and were rated good quality. Patients in all 6 trials were instructed to take trial medication within 1 hour of migraine ® onset and while the pain remained mild. In all 6 trials, Treximet was superior to placebo on rates of 2-hour pain-free and 24-hour sustained pain-free. We calculated separate pooled relative risk estimates for the subgroup of 4 trials (TRX101998, TRX101999, TRX103632, TRX103635; N=1537) that enrolled patients regardless of their triptan treatment history and for the subgroup of 2 trials, which required prior poor response or intolerance (TRX106571 and TRX106573; N=535). For 2-hour pain-free outcomes, compared to the combined estimate of benefit from the 4 trials that enrolled patients regardless of their prior triptan treatment history (relative risk, 3. For 24-hour sustained pain-free outcomes, however, compared with the combined estimate of benefit from the 4 trials of patients with an unspecified triptan treatment history ® (relative risk, 3. Protocols TRX103632 and TRX103635 also evaluated within-subject consistency of 2- hour pain-free and 24-hour sustained pain-free outcomes in 973 of 1135 (86%) patients who ® 117 treated at least 3 attacks with Treximet. The rate of patients who were pain-free at 2 hours ® postdose in at least 2 of the first 3 attacks treated with Treximet was 52% to 55% across both trials. The rates of patients with a sustained pain-free response through 24 hours postdose in at ® least 2 of the first 3 attacks treated with Treximet ranged from 14% to 15% across the 2 trials. Subgroup analyses of the patients randomized to the sequence with no interspersed placebo Triptans Page 39 of 80 Final Report Update 4 Drug Effectiveness Review Project treatment found similar rates of 2-hour pain-free and 24-hour sustained pain-free, which suggests against significant period effects. In patients randomized to the sequence that contained 4 ® consecutive treatment periods of Treximet , 21% (18/84) in TRX103635 and 28% (27/95) in TRX103632 had 2-hour pain-free outcomes in all 4 attacks. Of the 600 patients enrolled, 565 (94%) treated at least 1 migraine and 362 (64%) completed the 12-month trial and were included in the quality of life analyses. Measurement of clinically relevant improvement was based on changes of +6. Proportions of patients who achieved clinically relevant improvements at 12 months were 60% for the Role Restrictive domain, 56% for the Role Preventive domain, and 64% for the Emotional Function domain. Fixed-dose tablets containing a triptan compared with co- administration of its individual triptan and analgesic component agents ® We found no evidence on the comparison of Treximet and co-administration of its individual components, reformulated, rapid-release sumatriptan 85 mg and naproxen 500 mg. What are the comparative incidence and nature of complications (serious or life-threatening or those that may adversely effect compliance) of different triptans in adult patients being treated for migraine? Monotherapy compared with monotherapy There are no comparative studies concerning serious, life-threatening events associated with triptan use. But data on rare or life-threatening complications is available for the various forms of sumatriptan. A published review of the safety of sumatriptan examined adverse events in clinical 119 trials and postmarketing surveillance data. In 1998, 16 serious cardiovascular events following use of subcutaneous sumatriptan and 11 following use of conventional oral sumatriptan were reported to the voluntary postmarketing surveillance system.
Multiple attack study on the available triptans in Italy versus placebo purchase viagra plus 400mg without a prescription. Progress in clinical neurosciences: A systematic review of the use of triptans in acute migraine best 400 mg viagra plus. Pharmacological treatments for acute migraine: quantitative systematic review. Triptans Page 49 of 80 Final Report Update 4 Drug Effectiveness Review Project 53. Wilding IR, Clark D, Wray H, Alderman J, Muirhead N, Sikes CR. In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers. The bioequivalence of standard sumatriptan tablets and two encapsulated forms of sumatriptan. Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Silberstein SD, Cady RK, Sheftell FD, Almas M, Parsons B, Albert KS. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Unpublished Protocol 39 Supplemental Dossier on Maxalt compiled October 2008 for the Drug Effectiveness Review Project. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine. Klapper J, Lucas C, Rosjo O, Charlesworth B, group Zs. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Spierings ELH, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine: A double- blind, randomized, parallel-group, optimum-dose comparison. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Triptans Page 50 of 80 Final Report Update 4 Drug Effectiveness Review Project 71. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. A double-blind, placebo-controlled trial of almotriptan. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Oral almotriptan in the treatment of migraine: a dose finding study.
10 of 10 - Review by S. Kan
Votes: 289 votes
Total customer reviews: 289